b'THE FIRST AND ONLY SSATHAT DELIVERS 1-4THE FIRST AND ONLY SSATHAT DELIVERSActor portrayalSince 2017, over half of oncologists initiated treatment with Somatuline Depot for their newly diagnosed patients with GEP-NETs and carcinoid syndrome 5 **Based on IQVIA insurance claims for oncologists with new and continuing patients during November 2017October 2020, subject to change without notice. SSA=somatostatin analog; PFS=progression-free survival; GEP-NETs=gastroenteropancreatic neuroendoctrine tumors.INDICATIONSSOMATULINE DEPOT (lanreotide) is a somatostatin analog indicated for: the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.IMPORTANT SAFETY INFORMATIONContraindications SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.Warnings and Precautions Cholelithiasis and Gallbladder Sludge SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately. Hypoglycemia or Hyperglycemia Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.Cardiovascular Abnormalities SOMATULINE DEPOT may decrease heart rate. In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.Please see Important Safety Information and Brief Summary of Full Prescribing Information, on adjacent pages.'